Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation

Anat Galor, Victor L Perez Quinones, Jeffrey P. Hammel, Careen Y. Lowder

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Purpose: Anti-tumor necrosis factor α (anti-TNF-α) agents are being used increasingly in refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab to determine whether these medications are equally efficacious in controlling ocular inflammation. Design: Exploratory retrospective analysis. Participants: Patients with ocular inflammatory disease on an anti-TNF-α agent (etanercept, infliximab). Methods: Case records of 22 patients treated with anti-TNF-α therapy were reviewed for demographic information, ocular and systemic diagnosis, duration and dose of anti-TNF-α treatment, concomitant ocular and systemic immunosuppressive medications, and treatment response. Main Outcome Measures: Uveitis recurrence rate, initial treatment response, treatment response, and medication use at 6 months, 1 year, and last visit. Results: Patients treated with infliximab had a significant decrease in uveitis recurrences after starting therapy compared with those treated with etanercept (59% vs. 0%, P = 0.004). One year after treatment initiation and at final visit, more infliximab-treated patients had an improvement in their ocular inflammation (100% vs. 33%, P = 0.002, and 94% vs. 0%, P<0.001, respectively) and a decreased requirement for topical prednisolone acetate 1% (94% vs. 33%, P = 0.009, and 89% vs. 29%, P = 0.007, respectively) compared with those treated with etanercept. No significant differences in the use of oral corticosteroids and immunosuppressive agents were noted between the 2 groups at 6 months, 1 year, and final visit. Conclusions: Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids.

Original languageEnglish
Pages (from-to)2317-2323
Number of pages7
JournalOphthalmology
Volume113
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Inflammation
Uveitis
Eye Diseases
Therapeutics
Immunosuppressive Agents
Recurrence
Etanercept
Infliximab
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Steroids
Demography
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation. / Galor, Anat; Perez Quinones, Victor L; Hammel, Jeffrey P.; Lowder, Careen Y.

In: Ophthalmology, Vol. 113, No. 12, 01.12.2006, p. 2317-2323.

Research output: Contribution to journalArticle

Galor, Anat ; Perez Quinones, Victor L ; Hammel, Jeffrey P. ; Lowder, Careen Y. / Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation. In: Ophthalmology. 2006 ; Vol. 113, No. 12. pp. 2317-2323.
@article{6aa2d54df4e9457dab845a6fe38639df,
title = "Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation",
abstract = "Purpose: Anti-tumor necrosis factor α (anti-TNF-α) agents are being used increasingly in refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab to determine whether these medications are equally efficacious in controlling ocular inflammation. Design: Exploratory retrospective analysis. Participants: Patients with ocular inflammatory disease on an anti-TNF-α agent (etanercept, infliximab). Methods: Case records of 22 patients treated with anti-TNF-α therapy were reviewed for demographic information, ocular and systemic diagnosis, duration and dose of anti-TNF-α treatment, concomitant ocular and systemic immunosuppressive medications, and treatment response. Main Outcome Measures: Uveitis recurrence rate, initial treatment response, treatment response, and medication use at 6 months, 1 year, and last visit. Results: Patients treated with infliximab had a significant decrease in uveitis recurrences after starting therapy compared with those treated with etanercept (59{\%} vs. 0{\%}, P = 0.004). One year after treatment initiation and at final visit, more infliximab-treated patients had an improvement in their ocular inflammation (100{\%} vs. 33{\%}, P = 0.002, and 94{\%} vs. 0{\%}, P<0.001, respectively) and a decreased requirement for topical prednisolone acetate 1{\%} (94{\%} vs. 33{\%}, P = 0.009, and 89{\%} vs. 29{\%}, P = 0.007, respectively) compared with those treated with etanercept. No significant differences in the use of oral corticosteroids and immunosuppressive agents were noted between the 2 groups at 6 months, 1 year, and final visit. Conclusions: Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids.",
author = "Anat Galor and {Perez Quinones}, {Victor L} and Hammel, {Jeffrey P.} and Lowder, {Careen Y.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.ophtha.2006.04.038",
language = "English",
volume = "113",
pages = "2317--2323",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation

AU - Galor, Anat

AU - Perez Quinones, Victor L

AU - Hammel, Jeffrey P.

AU - Lowder, Careen Y.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: Anti-tumor necrosis factor α (anti-TNF-α) agents are being used increasingly in refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab to determine whether these medications are equally efficacious in controlling ocular inflammation. Design: Exploratory retrospective analysis. Participants: Patients with ocular inflammatory disease on an anti-TNF-α agent (etanercept, infliximab). Methods: Case records of 22 patients treated with anti-TNF-α therapy were reviewed for demographic information, ocular and systemic diagnosis, duration and dose of anti-TNF-α treatment, concomitant ocular and systemic immunosuppressive medications, and treatment response. Main Outcome Measures: Uveitis recurrence rate, initial treatment response, treatment response, and medication use at 6 months, 1 year, and last visit. Results: Patients treated with infliximab had a significant decrease in uveitis recurrences after starting therapy compared with those treated with etanercept (59% vs. 0%, P = 0.004). One year after treatment initiation and at final visit, more infliximab-treated patients had an improvement in their ocular inflammation (100% vs. 33%, P = 0.002, and 94% vs. 0%, P<0.001, respectively) and a decreased requirement for topical prednisolone acetate 1% (94% vs. 33%, P = 0.009, and 89% vs. 29%, P = 0.007, respectively) compared with those treated with etanercept. No significant differences in the use of oral corticosteroids and immunosuppressive agents were noted between the 2 groups at 6 months, 1 year, and final visit. Conclusions: Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids.

AB - Purpose: Anti-tumor necrosis factor α (anti-TNF-α) agents are being used increasingly in refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab to determine whether these medications are equally efficacious in controlling ocular inflammation. Design: Exploratory retrospective analysis. Participants: Patients with ocular inflammatory disease on an anti-TNF-α agent (etanercept, infliximab). Methods: Case records of 22 patients treated with anti-TNF-α therapy were reviewed for demographic information, ocular and systemic diagnosis, duration and dose of anti-TNF-α treatment, concomitant ocular and systemic immunosuppressive medications, and treatment response. Main Outcome Measures: Uveitis recurrence rate, initial treatment response, treatment response, and medication use at 6 months, 1 year, and last visit. Results: Patients treated with infliximab had a significant decrease in uveitis recurrences after starting therapy compared with those treated with etanercept (59% vs. 0%, P = 0.004). One year after treatment initiation and at final visit, more infliximab-treated patients had an improvement in their ocular inflammation (100% vs. 33%, P = 0.002, and 94% vs. 0%, P<0.001, respectively) and a decreased requirement for topical prednisolone acetate 1% (94% vs. 33%, P = 0.009, and 89% vs. 29%, P = 0.007, respectively) compared with those treated with etanercept. No significant differences in the use of oral corticosteroids and immunosuppressive agents were noted between the 2 groups at 6 months, 1 year, and final visit. Conclusions: Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids.

UR - http://www.scopus.com/inward/record.url?scp=33751546583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751546583&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.04.038

DO - 10.1016/j.ophtha.2006.04.038

M3 - Article

C2 - 16996615

AN - SCOPUS:33751546583

VL - 113

SP - 2317

EP - 2323

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 12

ER -